Analysis of Humoral Immune Responses in Chikungunya Virus (CHIKV)-Infected Patients and Individuals Vaccinated With a Candidate CHIKV Vaccine

dc.creatorHenss, Lisa
dc.creatorYue, Constanze
dc.creatorvon Rhein, Christine
dc.creatorTschismarov, Roland
dc.creatorLewis-Ximenez, Lia Laura
dc.creatorDölle, Albert
dc.creatorBaylis, Sally A.
dc.creatorSchnierle, Barbara S.
dc.date2021-02-07T12:43:00Z
dc.date2021-02-07T12:43:00Z
dc.date2020
dc.date.accessioned2023-09-26T22:45:39Z
dc.date.available2023-09-26T22:45:39Z
dc.identifierHENSS, Lisa et al. Analysis of Humoral Immune Responses in Chikungunya Virus (CHIKV)-Infected Patients and Individuals Vaccinated With a Candidate CHIKV Vaccine. The Journal of Infectious Diseases, v. 221, p. 1713-1723, 2020.
dc.identifier1537-6613
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/45978
dc.identifier10.1093/infdis/jiz658
dc.identifier0022-1899
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8882861
dc.descriptionBackground. Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes severe flu-like symptoms. The acute symptoms disappear after 1 week, but chronic arthralgia can persist for years. In this study, humoral immune responses in CHIKV-infected patients and vaccinees were analyzed. Methods. Alphavirus neutralization activity was analyzed with pseudotyped lentiviral vectors, and antibody epitope mapping was performed with a peptide array. Results. The greatest CHIKV neutralization activity was observed 60–92 days after onset of symptoms. The amount of CHIKVspecific antibodies and their binding avidity and cross-reactivity with other alphaviruses increased over time. Chikungunya virus and o’nyong-nyong virus (ONNV) were both neutralized to a similar extent. Linear antibody binding epitopes were mainly found in E2 domain B and the acid-sensitive regions (ASRs). In addition, serum samples from healthy volunteers vaccinated with a measlesvectored chikungunya vaccine candidate, MV-CHIK, were analyzed. Neutralization activity in the samples from the vaccine cohort was 2- to 6-fold lower than in samples from CHIKV-infected patients. In contrast to infection, vaccination only induced crossneutralization with ONNV, and the E2 ASR1 was the major antibody target. Conclusions. These data could assist vaccine design and enable the identification of correlates of protection necessary for vaccine efficacy.
dc.formatapplication/pdf
dc.languageeng
dc.publisherOxford University Press
dc.rightsrestricted access
dc.subjectAlphavírus
dc.subjectAnticorpo
dc.subjectChikungunya
dc.subjectNeutralização
dc.subjectAlphavirus
dc.subjectAntibody
dc.subjectChikungunya
dc.subjectNeutralization
dc.titleAnalysis of Humoral Immune Responses in Chikungunya Virus (CHIKV)-Infected Patients and Individuals Vaccinated With a Candidate CHIKV Vaccine
dc.typeArticle


Este ítem pertenece a la siguiente institución